Although a small patient population, results suggest improvement in secondary hyperparathyroidism, oxidative stress, and ventricular function (LVEF). Serum PTH was reduced at 14 weeks from 104.8 to 73.8 pg/mL, Plasma 8-isoprostane a marker of oxidative stress was reduced at 14 weeks to 117.8 from 136.1 pg/ml. With baseline EF of 24.3 ± 1.7% at entry was improved to 31.3 ± 4.3%. Here, PTH is linked to secondary hyperparathyroidism.